The relevance of drug sequence in combination chemotherapy

Drug Resistance Updates

Volumn 3, Issue 6, 2000, Pages 335-356

  Shah, Manish A ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PLATINUM; RALTITREXED; TAXANE DERIVATIVE; VINCA ALKALOID;

CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 0034503482     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0165     Document Type: Article

References (231)

1. Principles of Cancer Management: Chemotherapy
2. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
3. Results of combination chemotherapy of non-Hodgkin's lymphoma
4. Combination chemotherapy and survival in advanced Hodgkin's disease
5. The use of drugs in combination for the treatment of cancer: Rationale and results
6. Combination chemotherapy of acute lymphocytic leukemia of childhood
7. Evidence that drugs in multiple combinations have materially advanced the treatment of human malignancies
8. Systemic chemotherapy for advanced breast cancer
9. Tumor size, sensitivity to therapy, and design of treatment schedules
10. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
11. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
12. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
13. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKls)
14. Cyclins and cell cycle checkpoints
15. Conceptual basis for advances in the systemic drug therapy of breast cancer
16. Experimental evaluation of potential anticancer antents - XIV. Further studies on certain basic concepts underlying chemotherapy of leukemia
17. Experimental evaluation of potential anticancer agents - XII. On the criteria and kinetics associated with curability of experimental leukemia
18. Mutations of bacteria from virus sensitivity to virus resistance
19. Cell cycle characteristics of human solid tumors in vivo
20. Cell kinetics in normal tissues and in tumors of the young
21. A model for tumor response to chemotherapy: An integration of the stem cell and somatic mutation hypotheses
22. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
23. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results
24. Clinical studies of combination chemotherapy in cancer
25. Synergism, antagonism, and potentiation in chemotherapy: An overview
26. The biochemistry of P-glycoprotein-mediated multidrug resistance
27. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
28. Future perspectives for the development of P-glycoprotein modulators
29. Kinetics and thermodynamics of the interaction of 5-fluoro- 2′-deoxyuridylate with thymidylate synthase
30. Biochemical modulation of fluorouracil with leucovorin and interferon: Preclinical and clinical investigations
31. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid
32. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project
33. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
34. The problem of synergy and antagonism of combined drugs
35. Exploitable mechanisms in combined radiotherapy-chemotherapy. The concept of additivity
36. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
37. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines
38. In vitro toxicity of taxol based anticancer drug combinations on human hematopoietic progenitors
39. What is synergy?
40. The search for synergy: A critical review from response surface perspective
41. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities
42. CDK inhibitors: Positive and negative regulators of GI -phase progression
43. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
44. Promotion of microtubule assembly in vitro by taxol
45. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins
46. Taxol stabilizes microtubules in mouse fibroblast cells
47. CDK4 down-regulation induced by paclitaxel is associated with G I arrest in gastric cancer cells
48. Paclitaxel inhibits progression of mitotic cells to GI phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase
49. A phase I trial of taxol given by a 6-hour intravenous infusion
50. Activation of p34cdc2 coincident with taxol-induced apoptosis
51. Accumulation of cyclin BI, activation of cyclin BI-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol
52. Temporal and spatial control of cyclin BI destruction in metaphase
53. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1 which inhibits p34Cdc2 kinase
54. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle
55. Raf-l/bcl-2 phosphorylation: A step from microtubule damage to cell death
56. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis
57. Molecular effects of paclitaxel: Myths and reality (a critical review)
58. Differential Taxol-dependent arrest of transformed and nontransformed cells in the GI phase of the cell cycle, and specific related mortality of transformed cells
59. Paclitaxel-Induced cell death
60. An antiinflammatory cum immodulatory piperidinylbenzopyranone from dysoxylum binectariferum: Isolation, structure, and total synthesis
61. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
62. Flavopiridol induces GI arrest with inhibition of cyclin-dependent kinase CDC2 and CDK4 in human breast carcinoma cells
63. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural anologs
64. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
65. Inappropriate cell cycle progression enhances the induction of apoptosis by flavopiridol in Taxol treated gastric cancer cells
66. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of Sequence of administration
67. The in vitro effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
68. A phase I trial of weekly sequential bryostatin (Bryo) and paclitaxel in patients with advanced solid tumors
69. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C
70. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin-I correlates with the dephosphorylation of cyclin-dependent kinase 2
71. Phase I study of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol
72. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: Role of G2 arrest and DNA double strand breaks
73. Premature mitosis induced in mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-dimethylaminopurine
74. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells
75. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro
76. Recent insights into platinum drug resistance in cancer
77. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia
78. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: Possible explanation for failure of combination therapy
79. DNA damage and cell cycle checkpoints
80. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
81. Increased accumulation of p53 protein in cisplatin-resistant cell lines
82. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
83. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells
84. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines
85. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells
86. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro
87. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine
88. Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro
89. Influence of taxol: Cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells
90. Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo
91. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules
92. Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro
93. Sequences of taxol and cisplatin: A phase I and pharmacologic study
94. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells
95. Clinical pharmacology of carboplatin administered in combination with paclitaxel
96. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European cancer centre
97. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
98. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines
99. Synergistic action of paclitaxel with tiazofurin and methotrexate in human breast cancer cells: Schedule-dependence
100. Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells
101. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors
102. Mechanism of inhibition of cell proliferation by Vinca alkaloids
103. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine
104. Antimicrotuble agents
105. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review
106. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4
107. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
108. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines
109. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines
110. Vinorelbine tartrate and paclitaxel combinations: Enhanced activity against in vivo P388 murine leukemia cells
111. The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells
112. Combination paclitaxel and vinorelbine therapy: In vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines
113. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro
114. Combination effects of KW-2307 with taxol against murine and human tumors in vitro and in vivo
115. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule
116. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer
117. Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma
118. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure
119. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma
120. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer
121. Taxol and vinorelbine: A new active combination for disseminated malignant melanoma
122. A phase I study of sequential vinorelbine followed by paclitaxel
123. Topoisomerase interactive agents
124. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: A literature survey
125. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs
126. Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma
127. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin BI activity induced by doxorubicin in synchronized P388 cells
128. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
129. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
130. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer
131. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity
132. Phase I studies with a novel nucleoside analog gemcitabine
133. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
134. Tumor cell resistance to DNA topoisomerase II inhibitors: New developments
135. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC- 141540) in L1210 leukemia
136. Structure, activity relationships of podophyllin congeners that inhibit topoisomerase II
137. Paclitaxel in combination with doxorubicin or etoposide. Possible antagonism in vitro
138. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines
139. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines
140. Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer
141. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer
142. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: Comparison of two Phase II trials
143. Plant anti-tumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata
144. The current status of camptothecin analogues as antitumor agents
145. Action of camptothecin on mammalian cells in culture
146. Topoisomerase I inhibitors: Topotecan and irinotecan
147. Camptothecin induces protein-linked DNA breaks via mammalian Topoisomerase I
148. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by Camptothecin
149. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient GI arrest followed by necrotic cell death
150. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc2/cyclin B
151. Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax, and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone
152. Unscheduled activation of cyclin BI/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells ungroing apoptosis induced by DNA damage
153. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan
154. Flavopiridol potentiates the SN-38 induced apoptosis in association with down-regulation of cyclin dependent kinase inhibitor p21/Waf1/cip1 in HCT-116 cells
155. P21 is necessary for the p53 mediated GI arrest in human cancer cells
156. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
157. Cell cycle arrest versus cell death in cancer therapy
158. Loss of p21 Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism
159. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
160. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, paclitaxel, topotecan, and gemcitabine
161. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
162. Cytotoxic effects of topotecan combined with various anti-cancer agents in human cancer cell lines
163. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
164. The S-phase cytotoxicity of camptothecin
165. Low-level taxane exposure increases the activity of topoisomerase I targeted agents
166. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study
167. Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study
168. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer
169. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity
170. Phase I/II study of docetaxel (Doc) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC)
171. Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors
172. A phase I dose escalation and sequencing study of taxotere and continuous infusion topotecan in patients with advance malignancies
173. Combined modalities of resistance in etoposide-resistant human KB cell lines
174. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines
175. Topoisomerase II as a target of anticancer drug action in mammalian cells
176. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlick ascites tumor cells
177. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody
178. Effects of CPT-11 in combination with other anti-cancer agents in culture
179. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
180. Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells
181. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells
182. Involvement of nucleic acid synthesis in killing mechanisms of topoisomerase poisons
183. Topoisomerase I inhibitors: Selectivity and cellular resistance
184. Topoisomerase II: A specific marker for cellproliferation
185. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo
186. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
187. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity
188. Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer
189. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group trial
190. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors
191. A phase 1 and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
192. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide
193. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
194. Antimetabolites
195. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells
196. Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line
197. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose
198. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo
199. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
200. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines
201. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (Irinotecan) in a human colorectal carcinoma cell line
202. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
203. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
204. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
205. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group
206. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
207. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
208. Phase III study of Irinotecan with Fluorouracil versus Fluorouracil alone in metastatic colorectal carcinoma
209. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines
210. Raltitrexed: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
211. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: Preliminary results from phase I clinical trials
212. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
213. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity
214. Interactions and cross-resistance patterns between various schedules of 5-FU and the new folate-based thymidylate synthase inhibitor Tomudex (ZD1694)
215. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations
216. Combination therapy with infusional 5-FU and 'Tomudex' for patients with advanced colorectal cancer - A phase I study
217. Interim results of a phase I trial suggest that 'Tomudex' (raltitrexed) may act synergistically with 5-FU in patients with advanced colorectal cancer
218. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. Purification, physicochemical properties, structural determination and biological activities
219. Potent and specific inhibitors of PKC of microbial origin
220. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
221. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoind carcinoma, A431 cells
222. UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
223. GI phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as the induction of CDK inhibitor p21/CIP/WAFI/Sdil in p53-mutated human epidermoid carcinoma A431 cells
224. The retinoblastoma gene product is a negative modulator of the apoptotic pathway
225. Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle
226. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate
227. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner
228. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models